Patient | Age, yrs | Disease Duration, yrs | VAS | Swollen Joint Count* | Tender Joint Count | ESR | DMARD | Biologics |
---|---|---|---|---|---|---|---|---|
1 | 55 | 29 | 52 | 9 | 2 | 15 | MTX | TNF |
2 | 55 | 4 | 72 | 10 | 7 | 19 | SLZ, MTX | 0 |
3 | 62 | 20 | 83 | 11 | 13 | 19 | MTX | 0 |
4 | 67 | 37 | 24 | 6 | 5 | 46 | LFN, HCQ | 0 |
5 | 57 | 5 | 65 | 12 | 22 | 14 | MTX | TNF |
6 | 45 | 23 | 32 | 8 | 4 | 22 | MTX | 0 |
7 | 59 | 37 | 70 | 16 | 11 | 22 | MTX, HCQ | 0 |
↵* SJC according to at least 50% (4/7) of the clinical healthcare professionals. VAS: 100-mm visual analog scale; ESR: erythrocyte sedimentation rate; DMARD: disease-modifying antirheumatic drug; MTX: methotrexate; TNF: tumor necrosis factor; SLZ: sulfasalazine; LFN: leflunomide; HCQ: hydroxychloroquine.